Search Results for "f"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for f. Results 201 to 210 of 864 total matches.

Varenicline (Chantix) Warnings: Risk Versus Benefit

   
The Medical Letter on Drugs and Therapeutics • Jul 14, 2008  (Issue 1290)
School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New ...
The nicotine receptor partial agonist varenicline (Chantix - Pfizer) appears to be the most effective drug available to treat tobacco dependence, but the FDA has added a warning to the package insert about neuropsychiatric symptoms and exacerbations of preexisting psychiatric illness associated with its use. Agitation, hostility, depressed mood, suicidal ideation and suicidal behavior have been reported as postmarketing adverse events in patients who took varenicline and stopped smoking and in those who took the drug and continued to smoke.
Med Lett Drugs Ther. 2008 Jul 14;50(1290):53 |  Show IntroductionHide Introduction

ECGs Before Stimulants in Children

   
The Medical Letter on Drugs and Therapeutics • Jul 28, 2008  (Issue 1291)
School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New ...
The American Heart Association (AHA) recently published a statement saying that it would be reasonable to obtain an electrocardiogram (ECG) in children being evaluated for stimulant drug therapy for attention deficit hyperactivity disorder (ADHD). A subsequent news release in conjunction with the American Academy of Pediatrics provided a clarification, saying that it would be reasonable to consider obtaining an ECG in such children.
Med Lett Drugs Ther. 2008 Jul 28;50(1291):60 |  Show IntroductionHide Introduction

Zingo for Local Analgesia in Children

   
The Medical Letter on Drugs and Therapeutics • Aug 25, 2008  (Issue 1293)
., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H ...
The FDA has approved the marketing of a new device for delivering lidocaine to the skin of children undergoing a venipuncture or intravenous (IV) line placement. Zingo (Anesiva) is a powder intradermal injection system.
Med Lett Drugs Ther. 2008 Aug 25;50(1293):68 |  Show IntroductionHide Introduction

In Brief: Melamine

   
The Medical Letter on Drugs and Therapeutics • Oct 20, 2008  (Issue 1297)
Hospital, Copenhagen Dan M. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R. Simons ...
Melamine present in infant formula and other milk products has been associated with widespread illness and some deaths among infants in China. It was also identified in pet food sold in North America after a large number of pets became ill and some died. In both the infants and the pets, renal injury appeared to be the cause.1Melamine (C3H6N6) is a heterocyclic compound, two-thirds nitrogen by weight, that is slightly soluble in water. When combined with formaldehyde, it forms melamine resin, which has a wide variety of industrial applications including the manufacturing of kitchenware,...
Med Lett Drugs Ther. 2008 Oct 20;50(1297):81 |  Show IntroductionHide Introduction

In Brief: New Propellants for Albuterol Metered-Dose Inhalers

   
The Medical Letter on Drugs and Therapeutics • Nov 03, 2008  (Issue 1298)
of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New York ...
Inhaled drugs for asthma are available in the US mainly in pressurized metered-dose inhalers (MDIs), which require a propellant, and dry powder inhalers, which do not. The chlorofluorocarbon (CFC) propellants in MDIs are being replaced by hydrofluoroalkane (HFA) propellants for environmental reasons: CFCs contribute to the depletion of the ozone layer. December 31, 2008 will be the last day that albuterol MDIs using CFC propellants can be sold in the US. The FDA is expected to announce a termination date for other CFC-containing products in the near future.Three HFA albuterol inhalers and one...
Med Lett Drugs Ther. 2008 Nov 3;50(1298):85 |  Show IntroductionHide Introduction

Vigabatrin (Sabril) for Epilepsy

   
The Medical Letter on Drugs and Therapeutics • Feb 22, 2010  (Issue 1332)
., M.P.H., F.A.C.P., Harvard Medical School EDITOR: Jean-Marie Pflomm, Pharm.D. ASSISTANT EDITORS ...
The FDA has approved vigabatrin (vye gá ba trin; Sabril – Lundbeck) for oral use as add-on therapy for complex partial seizures in adults who are refractory to several antiepileptic drugs and as monotherapy for infantile spasms. Vigabatrin has been available in other countries for many years. Because of its potential for retinal toxicity, it will be available in the US only through a restricted distribution program called SHARE (Support, Help and Resources for Epilepsy). Prescribers and pharmacists distributing the drug must register, and patients must undergo visual field testing.
Med Lett Drugs Ther. 2010 Feb 22;52(1332):14-6 |  Show IntroductionHide Introduction

Saxagliptin (Onglyza) for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Nov 02, 2009  (Issue 1324)
: Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School EDITOR: Jean-Marie Pflomm, Pharm.D ...
Saxagliptin (Onglyza - Bristol-Myers Squibb), the second oral dipeptidyl peptidase-4 (DPP-4) inhibitor to be marketed in the US, has been approved by the FDA for treatment of adults with type 2 diabetes.
Med Lett Drugs Ther. 2009 Nov 2;51(1324):85-6 |  Show IntroductionHide Introduction

Nirsevimab (Beyfortus) for Prevention of Severe RSV Disease in Young Children

   
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023  (Issue 1685)
syncytial virus (RSV) fusion (F) protein-directed long-acting monoclonal antibody. Indication: FDA ...
The FDA has approved nirsevimab-alip (Beyfortus – AstraZeneca/Sanofi), a long-acting monoclonal antibody, for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season, and in children ≤24 months old who are at increased risk for severe RSV disease through their second RSV season. Nirsevimab is the first drug to be approved for protection of all infants during their first RSV season.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):145-7   doi:10.58347/tml.2023.1685a |  Show IntroductionHide Introduction

COVID-19 Update: mRNA COVID-19 Vaccines and Myocarditis

   
The Medical Letter on Drugs and Therapeutics • Jul 21, 2025  (Issue 1733)
significance of these f ndings is unknown.2 1. FDA. FDA approves required updated warning in labeling of mRNA ...
The FDA has required the manufacturers of the mRNA COVID-19 vaccines Comirnaty (Pfizer-BioNTech) and Spikevax (Moderna) to revise their labels to include updated information about the risks of myocarditis/pericarditis. The FDA requested that the manufacturers submit the proposed labeling changes or contest the agency's requirement for the safety update by May 17, 2025. As of June 4th, to our knowledge, the labels of Comirnaty and Spikevax have not been updated and neither manufacturer has submitted a rebuttal.
Med Lett Drugs Ther. 2025 Jul 21;67(1733):119   doi:10.58347/tml.2025.1733g |  Show IntroductionHide Introduction

Tetrabenazine (Xenazine) for Huntington's Chorea

   
The Medical Letter on Drugs and Therapeutics • Jan 26, 2009  (Issue 1304)
Einstein College of Medicine Sandip K. Mukherjee, M.D. F.A.C.C., Yale School of Medicine ADVISORY BOARD ...
Tetrabenazine (Xenazine - Ovation Pharmaceuticals), an old drug first synthesized 50 years ago for treatment of schizophrenia, was recently approved by the FDA for the treatment of chorea associated with Huntington's disease. It has been available in other countries for decades.
Med Lett Drugs Ther. 2009 Jan 26;51(1304):7-8 |  Show IntroductionHide Introduction